EBS · Emergent BioSolutions Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Q2 results significantly beat guidance with $234M revenue and $97M adjusted EBITDA (41% margin), but the company lowered full-year 2026 guidance, recorded a $191M non-cash Narcan impairment, and announced a ~$40M annualized cost restructuring in response to new naloxone competition.
- + Q2 revenue of $234M exceeded the high end of prior guidance, driven by accelerated MCM deliveries and new U.S. government contract awards.
- + Q2 adjusted EBITDA of $97M at 41% margin, a sharp year-over-year margin expansion.
- + MCM segment posted record-high Q2 revenue of $168M supported by $52.7M ACAM2000 and $64.5M BAT contract modifications and 20% international mix.
- + Restructuring plan expected to deliver approximately $40M in annualized net savings through workforce reductions, lab closures, and a building sale.
- − Full-year 2026 revenue guidance cut to $645–$675M from prior $720–$760M on naloxone pricing pressure.
- − Adjusted EBITDA guidance cut to $130–$150M from prior $155–$175M.
- − Narcan revenue fell 22% YoY to $52.4M as new 4mg OTC and 10mg prescription entrants intensified pricing competition.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filingsA newer filing dated 2026-08-06 has an earlier KPI extraction that does not meet current evidence-completeness requirements. Those figures remain withheld. The verified series below may not include the company's latest disclosures.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $132M | Six Months Ended June 30, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net loss -$176.8M
+$94.3M Depreciation & amortization
+$30.8M Income taxes
+$46.4M Total interest expense, net
+$191.3M Impairments
+$3.9M Inventory step-up provision
+$3M Changes in fair value of financial instruments
+$0.7M Severance and restructuring costs
+$0M Acquisition and divestiture costs
+$10.7M Loss (gain) on sale of business and assets held for sale
-$9.6M Settlement charges, net
-$5M Contingent consideration milestones
+$32.7M Loss (gain) on debt extinguishment
+$18.9M Stock-based compensation expense
-$0.3M Other, net
= Adjusted EBITDA $241M
|
|||
| Adjusted EBITDA (Trailing twelve months) non-GAAP | $241M | Twelve months ended June 30, 2026 | — |
| Adjusted EBITDA margin non-GAAP | 34% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted net income non-GAAP | $42.8M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted net income per diluted share non-GAAP | $0.83 | Six Months Ended June 30, 2026 | — |
| Capital expenditures | $2.1M | Q2 2026 | — |
| MCM Products segment adjusted gross margin non-GAAP | $116.1M | Q2 2026 | — |
|
|
|||
| Net Debt non-GAAP | $450M | As of June 30, 2026 | — |
| Net Leverage Ratio non-GAAP | 1.9 | Twelve months ended June 30, 2026 | — |
| Remaining share repurchase authorization | $46.5M | Q1 2026 | — |
| Shares repurchased | 0.9M | Q1 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EBS
this stock
Emergent BioSolutions Inc.
|
$348.15M | -48.5% | -28.8% | — | 19.1% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.0% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.7% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EBS | -5.9% | -1.4% | -20.0% | -3.5% | -48.5% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -5.5% | -1.2% | -32.4% | -3.7% | -60.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.